HYTN Secures Additional Permits to Expand International GMP Cannabis Exports
HYTN Innovations has secured new import permits from the UK Home Office and export permits from Health Canada, enabling the export of over 400 kilograms of GMP cannabis products. This development marks HYTN's strategic shift from a Canadian recreational cannabis producer to a global manufacturer of non-sterile pharmaceuticals.
The company's focus on international distribution aligns with its April 2024 corporate update, emphasizing its commitment to meeting GMP standards and addressing global market demands. HYTN's products meet both European and German Pharmacopoeia standards, demonstrating their quality commitment. The company expects to complete all permitted shipments by the end of Q1 2025.
HYTN Innovations ha ottenuto nuovi permessi di importazione dal Ministero dell'Interno del Regno Unito e permessi di esportazione da Health Canada, consentendo l'esportazione di oltre 400 chilogrammi di prodotti cannabis GMP. Questo sviluppo segna il cambiamento strategico di HYTN da produttore canadese di cannabis ricreativa a produttore globale di farmaci non sterili.
Il focus dell'azienda sulla distribuzione internazionale 猫 in linea con l'aggiornamento aziendale di aprile 2024, che enfatizza il suo impegno a rispettare gli standard GMP e a rispondere alle esigenze del mercato globale. I prodotti di HYTN soddisfano sia gli standard della Farmacopea Europea che quella tedesca, dimostrando il loro impegno per la qualit脿. L'azienda prevede di completare tutte le spedizioni autorizzate entro la fine del primo trimestre del 2025.
HYTN Innovations ha asegurado nuevos permisos de importaci贸n del Ministerio del Interior del Reino Unido y permisos de exportaci贸n de Health Canada, lo que permite la exportaci贸n de m谩s de 400 kilogramos de productos de cannabis GMP. Este desarrollo marca el cambio estrat茅gico de HYTN de productor canadiense de cannabis recreativo a fabricante global de productos farmac茅uticos no est茅riles.
El enfoque de la empresa en la distribuci贸n internacional se alinea con su actualizaci贸n corporativa de abril de 2024, enfatizando su compromiso de cumplir con los est谩ndares GMP y de atender la demanda del mercado global. Los productos de HYTN cumplen tanto con los est谩ndares de la Farmacopea Europea como con los de la Farmacopea Alemana, lo que demuestra su compromiso con la calidad. La empresa espera completar todos los env铆os permitidos antes del final del primer trimestre de 2025.
HYTN Innovations電� 鞓侁淡 雮措攵�搿滊秬韯� 靸堧鞖� 靾橃瀰 項堦皜鞕� Health Canada搿滊秬韯� 靾橃稖 項堦皜毳� 須嶋摑頃橃棳 400韨攴鸽灗 鞚挫儊鞚� GMP 雽�毵堨磮 鞝滍拡 靾橃稖鞚� 臧�電ロ晿瓴� 頄堨姷雼堧嫟. 鞚� 氚滌爠鞚� HYTN鞚� 旌愲倶雼れ潣 霠堩伂毽棎鞚挫厴 雽�毵堨磮 靸濎偘鞛愳棎靹� 牍勲偞攴犾劚 鞚橃暯頀堨潣 旮�搿滊矊 鞝滌“鞐呾泊搿� 鞝勲灥鞝侅溂搿� 鞝勴櫂頃橂姅 瓴冹潉 鞚橂頃╇媹雼�.
須岇偓鞚� 甑牅 鞙犿喌鞐� 雽�頃� 歆戩鞚� 2024雲� 4鞗� 旮办梾 鞐呺嵃鞚错姼鞕� 鞚检箻頃橂┌, GMP 旮办 欷�靾� 氚� 旮�搿滊矊 鞁滌灔 靾橃殧鞐� 攵�鞚戫晿瓴犽嫟電� 鞚橃毳� 臧曥“頃╇媹雼�. HYTN鞚� 鞝滍拡鞚� 鞙犽熃 氚� 霃呾澕 鞎届爠 旮办鞚� 氇憪 於╈”頃橃棳 頀堨鞐� 雽�頃� 項岇嫚鞚� 氤挫棳欷嶋媹雼�. 須岇偓電� 2025雲� 1攵勱赴 毵愱箤歆� 氇摖 項堦皜霅� 氚办啞鞚� 鞕勲頃� 瓴冹溂搿� 鞓堨儊頃橁碃 鞛堨姷雼堧嫟.
HYTN Innovations a obtenu de nouveaux permis d'importation du minist猫re de l'Int茅rieur du Royaume-Uni et des permis d'exportation de Sant茅 Canada, permettant l'exportation de plus de 400 kilogrammes de produits de cannabis GMP. Ce d茅veloppement marque le tournant strat茅gique de HYTN, passant de producteur canadien de cannabis r茅cr茅atif 脿 fabricant mondial de m茅dicaments non st茅riles.
Le focus de l'entreprise sur la distribution internationale s'aligne avec sa mise 脿 jour corporative d'avril 2024, soulignant son engagement 脿 respecter les normes GMP et 脿 r茅pondre aux demandes du march茅 mondial. Les produits de HYTN r茅pondent aux normes de la Pharmacop茅e Europ茅enne et Allemande, prouvant leur engagement envers la qualit茅. L'entreprise s'attend 脿 compl茅ter toutes les exp茅ditions autoris茅es d'ici la fin du premier trimestre 2025.
HYTN Innovations hat neue Importgenehmigungen vom Innenministerium des Vereinigten K枚nigreichs und Exportgenehmigungen von Health Canada erhalten, wodurch der Export von 眉ber 400 Kilogramm GMP-Cannabisprodukten erm枚glicht wird. Dieser Schritt markiert den strategischen Wandel von HYTN vom kanadischen Produzenten von Freizeitchronen zu einem globalen Hersteller von nicht-sterilen Arzneimitteln.
Der Fokus des Unternehmens auf internationale Distribution steht im Einklang mit dem Unternehmensupdate von April 2024, das das Engagement betont, die GMP-Standards zu erf眉llen und die Bed眉rfnisse des globalen Marktes zu adressieren. Die Produkte von HYTN entsprechen sowohl den europ盲ischen als auch den deutschen Arzneib眉chervorschriften, was ihr Engagement f眉r Qualit盲t beweist. Das Unternehmen erwartet, bis zum Ende des ersten Quartals 2025 alle genehmigten Sendungen abzuschlie脽en.
- Secured new UK import and Canadian export permits for over 400kg of GMP cannabis products
- Strategic transformation from recreational to pharmaceutical-grade manufacturing
- Products meet European and German Pharmacopoeia standards
- Clear timeline for shipment completion by Q1 2025
- None.
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (鈥�HYTN鈥� or the 鈥淐辞尘辫补苍测鈥�), a pharmaceutical company specializing in pharmaceutical-grade cannabis manufacturing is pleased to announce that it has received a new set of import permits from the United Kingdom鈥檚 Home Office and corresponding export permits from Health Canada. These permits enable the fulfillment of international orders totaling over 400 kilograms of Good Manufacturing Practice (GMP) cannabis products, advancing HYTN鈥檚 global reach and operational capabilities.
This development underscores HYTN鈥檚 strategic transformation from a cannabis producer primarily serving the Canadian recreational market to a global manufacturer of non-sterile pharmaceuticals. The Company's focus on international distribution aligns with its corporate update published on April 5, 2024, which outlined its dedication to meeting stringent GMP standards and addressing the growing demands of regulated markets worldwide.
鈥淗YTN consistently meets the standards of the European Pharmacopoeia and the German Pharmacopoeia (Deutsches Arzneibuch, DAB) reflecting our dedication to quality and global expansion,鈥� states Jason Broome, Chief Operating Officer of HYTN. 鈥淲ith GMP systems and an efficient operational model, we are ready to meet the rising global demand for pharmaceutical-grade cannabis products.鈥�
The Company expects to complete all shipments permitted by these permits by the end of Q1 2025, highlighting its ability to meet international demand on schedule.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.
For more information contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the Company鈥檚 ability to fulfill or obtain purchase orders, and the Company鈥檚 expanded abilities to export its products globally. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company鈥檚 business include, among other things: the Company鈥檚 inability to fulfill or obtain purchase orders; the Company's failure to generate sufficient cash flow from operations to meet its current and future obligations; the Company's failure to access sources of debt and equity capital; changes to the regulatory framework within which the Company operates; competitive factors, pricing pressures, and supply and demand in the Company鈥檚 industry; and general economic and business conditions. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.
FAQ
What is the volume of GMP cannabis products HYTN (HYTNF) is permitted to export to the UK?
When will HYTN (HYTNF) complete its permitted UK cannabis shipments?
What pharmaceutical standards does HYTN (HYTNF) meet for its cannabis products?
How has HYTN (HYTNF) transformed its business strategy in 2024?
